Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.

To evaluate the impact of MHC antigen expression on the survival of patients with cancer, 77 human breast carcinomas were investigated for the expression of beta 2-microglobulin (beta 2m), HLA-A,B,C and HLA-DR. Thirty-one benign breast tumours were stained for comparison. The results for the carcino...

Descripción completa

Detalles Bibliográficos
Autores principales: Wintzer, H. O., Benzing, M., von Kleist, S.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971814/
https://www.ncbi.nlm.nih.gov/pubmed/2201398
_version_ 1782134991105294336
author Wintzer, H. O.
Benzing, M.
von Kleist, S.
author_facet Wintzer, H. O.
Benzing, M.
von Kleist, S.
author_sort Wintzer, H. O.
collection PubMed
description To evaluate the impact of MHC antigen expression on the survival of patients with cancer, 77 human breast carcinomas were investigated for the expression of beta 2-microglobulin (beta 2m), HLA-A,B,C and HLA-DR. Thirty-one benign breast tumours were stained for comparison. The results for the carcinomas were related to the survival data of the cancer patients. The expression of beta 2m, HLA-A,B,C and HLA-DR was significantly lower in malignant tumours compared to the benign lesions. Whereas all benign tumours were positive for beta 2m and HLA-A,B,C and 28/31 positive for HLA-DR the following positivity rates were found in carcinomas: 74/77 for beta 2m, 57/77 for HLA-A,B,C and 10/77 for HLA-DR. The follow-up (median 45 months) of 66 cancer patients for overall survival and of 65 patients for disease-free survival revealed no influence of beta 2m, HLA-A,B,C or HLA-DR expression on the prognosis of this cancer. In conclusion, experimental data indicating the importance of MHC antigens in anti-tumour responses are not confirmed by the analysis of cancer patient survival data. IMAGES:
format Text
id pubmed-1971814
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19718142009-09-10 Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas. Wintzer, H. O. Benzing, M. von Kleist, S. Br J Cancer Research Article To evaluate the impact of MHC antigen expression on the survival of patients with cancer, 77 human breast carcinomas were investigated for the expression of beta 2-microglobulin (beta 2m), HLA-A,B,C and HLA-DR. Thirty-one benign breast tumours were stained for comparison. The results for the carcinomas were related to the survival data of the cancer patients. The expression of beta 2m, HLA-A,B,C and HLA-DR was significantly lower in malignant tumours compared to the benign lesions. Whereas all benign tumours were positive for beta 2m and HLA-A,B,C and 28/31 positive for HLA-DR the following positivity rates were found in carcinomas: 74/77 for beta 2m, 57/77 for HLA-A,B,C and 10/77 for HLA-DR. The follow-up (median 45 months) of 66 cancer patients for overall survival and of 65 patients for disease-free survival revealed no influence of beta 2m, HLA-A,B,C or HLA-DR expression on the prognosis of this cancer. In conclusion, experimental data indicating the importance of MHC antigens in anti-tumour responses are not confirmed by the analysis of cancer patient survival data. IMAGES: Nature Publishing Group 1990-08 /pmc/articles/PMC1971814/ /pubmed/2201398 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Wintzer, H. O.
Benzing, M.
von Kleist, S.
Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.
title Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.
title_full Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.
title_fullStr Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.
title_full_unstemmed Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.
title_short Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.
title_sort lacking prognostic significance of beta 2-microglobulin, mhc class i and class ii antigen expression in breast carcinomas.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971814/
https://www.ncbi.nlm.nih.gov/pubmed/2201398
work_keys_str_mv AT wintzerho lackingprognosticsignificanceofbeta2microglobulinmhcclassiandclassiiantigenexpressioninbreastcarcinomas
AT benzingm lackingprognosticsignificanceofbeta2microglobulinmhcclassiandclassiiantigenexpressioninbreastcarcinomas
AT vonkleists lackingprognosticsignificanceofbeta2microglobulinmhcclassiandclassiiantigenexpressioninbreastcarcinomas

Ejemplares similares